Vasorelaxant effects of 1-nitro-2-phenylethene in rat isolated aortic rings.
Loeste Arruda-Barbosa, Karilane Maria Silvino Rodrigues, Francisco das Chagas Vasconcelos Souza-Neto, Gloria Pinto Duarte, Rosivaldo S Borges, Pedro Jorge Caldas Magalhães, Saad Lahlou
Index: Vascul. Pharmacol. 63(2) , 55-62, (2014)
Full Text: HTML
Abstract
Previously, we showed that nitro-2-phenylethane is a vasorelaxant constituent of the essential oil of Aniba canelilla. Here, we investigated the mechanisms underlying the vascular effects of 1-nitro-2-phenylethene (NPe), a structural analog of 1-nitro-2-phenylethane obtained synthetically, in rat isolated thoracic aortic preparations. At 0.1-100 μg/mL, NPe similarly relaxed endothelium-intact or endothelium-denuded aortic preparations pre-contracted with 60mM KCl or with phenylephrine (PHE, 1 μM). Vasorelaxant effects of NPe against PHE-induced contractions remained unaffected following blockade of potassium channels by TEA, and inhibition of either nitric oxide synthase by l-NAME, cyclooxygenase by indomethacin or guanylate cyclase by ODQ. In preparations maintained under Ca(2+)-free conditions, NPe significantly reduced the contractions induced (i) by PHE, but not those evoked by caffeine, (ii) by CaCl2 in either PHE (in the presence of 1 μM verapamil)- or KCl-stimulated preparations, (iii) by extracellular Ca(2+) restoration in thapsigargin-treated aortic preparations, and (iv) by the activator of protein kinase C phorbol-12,13-dibutyrate or the inhibitor of protein tyrosine phosphatase sodium orthovanadate. It is concluded that NPe induced an endothelium-independent vasorelaxation with potency greater than its structural analog 1-nitro-2-phenylethane. Such action appears to occur intracellularly probably through inhibition of contractile events that are clearly independent of Ca(2+) influx from the extracellular milieu.Copyright © 2014 Elsevier Inc. All rights reserved.
Related Compounds
Related Articles:
2014-05-22
[Oncogene 33(21) , 2717-27, (2014)]
2015-08-01
[J. Exp. Biol. 218 , 2610-9, (2015)]
2016-01-01
[Dev. Comp. Immunol. 54 , 55-65, (2015)]
2014-08-15
[Am. J. Physiol. Regul. Integr. Comp. Physiol. 307(4) , R414-25, (2014)]
2015-01-01
[Psychopharmacol. Ser. 232(1) , 47-56, (2015)]